Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10585020 | 0.84 | MAPT (0.53) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14439688 | 0.82 | POLB (0.56) | SMN1; SMN2LMNAKDM4EPOLBPKM | |
| SCHEMBL6400121 | 0.81 | PKM (0.57) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1059693 | 0.81 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL8362386 | 0.81 | NOS2 (0.50) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL30037937 | 0.79 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL757031 | 0.79 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL11743461 | 0.79 | KDM4E (0.58) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL11331858 | 0.79 | HDAC6 (0.58) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1374759 | 0.79 | NPC1 (0.71) | RAB9ANPC1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0318294-B1 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS (JP) | 1994-12-28 | — | — | EP | claimed |
| CN-114634491-B | Polycyclic compound for inhibiting RNA helicase DHX33 | 成都开悦生命科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4089089-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114634491-A | Polycyclic compound for inhibiting RNA helicase DHX33 | 成都开悦生命科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| WO-2006082107-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-08-10 | — | — | WO | disclosed |
| EP-0318294-B1 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-5125930-A | Polymeric cationic dyes including a quaternized pyridinium group | NIPPON CHEMICAL WORKS CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0318294-A2 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS CO., LTD (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0012300-B1 | COLOURED POLYMERIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION TO THE DYEING OF PAPER | BASF Aktiengesellschaft (DE) | 1982-12-01 | — | — | EP | disclosed |
| US-4271303-A | ISOINDOLE DYES FOR POLYESTERS | BASF AKTIENGESELLSCHAFT (DE) | 1981-06-02 | — | — | US | disclosed |
| US-4268668-A | FOR WOOL AND POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-19 | — | — | US | disclosed |
| US-4267319-A | CATIONIC DYES AND N-HETEROCYCLIC CATIONIC POLYMERS; PRINTING PAPER; ORANGE OR RED | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| EP-0012300-A2 | Coloured polymeric compounds, process for their preparation and their application to the dyeing of paper | BASF Aktiengesellschaft (DE) | 1980-06-25 | — | — | EP | disclosed |
| US-4051099-A | ISOINDOLES | CIBA-GEIGY CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | RAB9A 2726/4885NPC1 872/4885SMN1; SMN2 2706/4885 |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | DHX36, DDX21, DDX3X | RAB9A 1473/4885NPC1 1029/4885SMN1; SMN2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.